126 related articles for article (PubMed ID: 38884619)
21. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Harris SJ; Yarbrough CR; Abraham AJ
Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
[TBL] [Abstract][Full Text] [Related]
22. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients.
Calcaterra SL; Dafoe A; Tietbohl C; Thurman L; Bredenberg E
J Hosp Med; 2024 Jun; 19(6):460-467. PubMed ID: 38507276
[TBL] [Abstract][Full Text] [Related]
23. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
Wu LT; John WS; Mannelli P; Morse ED; Anderson A; Schwartz RP
Addict Sci Clin Pract; 2023 Aug; 18(1):45. PubMed ID: 37533071
[TBL] [Abstract][Full Text] [Related]
24. OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.
Tassey TE; Ott GE; Alvanzo AAH; Peirce JM; Antoine D; Buresh ME
J Subst Abuse Treat; 2022 Dec; 143():108895. PubMed ID: 36215913
[TBL] [Abstract][Full Text] [Related]
25. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
26. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
27. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
[TBL] [Abstract][Full Text] [Related]
28. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
29. Utilization of Medications for Opioid Use Disorder Among West Virginia Medicaid Enrollees Following Medicaid Coverage of Methadone.
Harris SJ; Landis RK; Li W; Stein BD; Saloner B
Subst Use Addctn J; 2024 Jan; 45(1):91-100. PubMed ID: 38258853
[TBL] [Abstract][Full Text] [Related]
30. Convenience without disclosure: a formative research study of a proposed integrated methadone and antiretroviral therapy service delivery model in Dar es Salaam, Tanzania.
Cooke A; Saleem H; Mushi D; Mbwambo J; Hassan S; Lambdin BH
Addict Sci Clin Pract; 2017 Oct; 12(1):23. PubMed ID: 29041950
[TBL] [Abstract][Full Text] [Related]
31. Geographic variation in availability of opioid treatment programs across U.S. communities.
Jehan S; Zahnd WE; Wooten NR; Seay KD
J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
[TBL] [Abstract][Full Text] [Related]
32. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
Haddad M; Coman E; Bifulco L
Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
[TBL] [Abstract][Full Text] [Related]
33. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
Huo S; Heil J; Salzman MS; Carroll G; Haroz R
J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Linkage to an Opioid Treatment Program and Methadone Treatment Retention following Hospital Discharge in a Safety-Net Setting.
Tierney HR; Takimoto SW; Azari S; Steiger S; Martin M
Subst Use Misuse; 2023; 58(9):1172-1176. PubMed ID: 37194561
[No Abstract] [Full Text] [Related]
35. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
[TBL] [Abstract][Full Text] [Related]
36. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
37. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
38. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
